Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

MABF2685-100UG Anti-Influenza A HA Antibody, clone rFluA-20 Antibody, Recombinant Monoclonal

MABF2685-100UG
100 μg  
Purchase on Sigma-Aldrich

Overview

Replacement Information
Description
Catalogue NumberMABF2685-100UG
DescriptionAnti-Influenza A HA Antibody, clone rFluA-20 Antibody, Recombinant Monoclonal
Alternate Names
  • Influenza A hemagglutinin
Background InformationInfluenza A viruses belong to the Orthomyxoviridae family and encapsidates the negative strand viral RNA that protects it from the action of nucleases. Its envelope membrane is reported to carry hemagglutinin, neuraminidase, and the ion channel protein M2. Hemagglutinin (HA) binds to the sialic acid present on the surface of its target host cells and the cell membrane then engulfs the virus through endocytosis and forms endosome. Following virus replication in host cell, neuraminidase removes sialic acid from infected cell surfaces and newly made viruses are released to infect more cells. Influenza A virus HA contains an antigenically variable globular head domain that has the receptor-binding site (RBS) for viral attachment and a more conserved stem domain that mediates fusion of viral and cell membranes in the endosome. Clone rFluA-20 displays high binding breadth and affinity to HA timers belonging to group 1 and group 2 viruses with EC50 in the range from 5 to 142 ng/mL. It is shown to bind with most HA from H1, H2, H3, H5, and H7 subtypes with high affinity (KD < 100 nM). It interacts with a novel epitope on the non-RBS side of the 220-loop and the adjacent 90-loop. (Ref.: Bangaru, S., et al. (2019). Cell. 177(5); 1136-1152).
References
Product Information
FormatPurified
PresentationPurified human recombinant monoclonal antibody IgG1 in PBS without azide.
Quality LevelMQ200
Applications
ApplicationAnti-Influenza A HA, clone rFluA-20, Cat. No. MABF2685, is a human recombinant monoclonal antibody that detects Influenza A hemagglutinin and is tested for use in ELISA and Neutralizing application.
Key Applications
  • ELISA
  • Neutralizing
Application NotesNeutralizing Activity: A representative lot of this antibody displayed neutralization activity in plaque assay with H3N2 A/Hong Kong/1/1968 virus causing a 3.8-fold reduction in the plaque size compared to the control. (Bangaru, S., et. al. (2019). Cell. 177(5):1136-1152.e18).

ELISA Analysis: A representative lot detected Influenza A HA in ELISA applications (Bangaru, S., et. al. (2019). Cell. 177(5):1136-1152.e18).

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
Biological Information
ImmunogenPBMCs from human donor, who was subjected to Flu vaccine multiple times, were immortalized and used generate human hybridoma cell lines secreting human mAbs.
EpitopeHemagglutinin head domain; non-RBS side of the 220-loop and the adjacent 90-loop
ClonerFluA-20
Concentration1.0 mg/mL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
HostHuman Recombinant
SpecificityClone rFluA-20 is human recombinant monoclonal antibody that detects Influenza A virus hemagglutinin in multiple strains.
IsotypeIgG1
Species Reactivity
  • Virus
Species Reactivity NoteInfluenza A Virus.
Antibody TypeRecombinant Monoclonal Antibody
Gene Symbol
  • HA
Purification MethodProtein G purified
Molecular Weight150 kDa calculated.
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Quality AssuranceEvaluated by ELISA with Recombinant influenza A H1N1 hemagglutinin.

ELISA Analysis: Various (titration, starting at 1 mg/mL) of this antibody detected recombinant Influenza A H1N1 hemagglutinin.
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsStable for 1 year at -10°C to -25°C from date of receipt. Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Packaging Information
Material Size100 μg
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
MABF2685-100UG 04061842667727

Documentation

Anti-Influenza A HA Antibody, clone rFluA-20 Antibody, Recombinant Monoclonal SDS

Title

Safety Data Sheet (SDS) 

Anti-Influenza A HA Antibody, clone rFluA-20 Antibody, Recombinant Monoclonal Certificates of Analysis

TitleLot Number
Anti-Influenza A HA, clone rFluA-20, Recombinant Monoclonal - 3819169 3819169
Anti-Influenza A HA, clone rFluA-20, Recombinant Monoclonal - 3862791 3862791
Anti-Influenza A HA, clone rFluA-20, Recombinant Monoclonal - 3884794 3884794
Anti-Influenza A HA, clone rFluA-20, Recombinant Monoclonal - 3891458 3891458
Anti-Influenza A HA, clone rFluA-20, Recombinant Monoclonal - 3891855 3891855
Anti-Influenza A HA, clone rFluA-20, Recombinant Monoclonal - 3927183 3927183
Anti-Influenza A HA, clone rFluA-20, Recombinant Monoclonal - 4061197 4061197
Anti-Influenza A HA, clone rFluA-20, Recombinant Monoclonal - 4067713 4067713
Anti-Influenza A HA, clone rFluA-20, Recombinant Monoclonal - Q3509831 Q3509831

References

Reference overviewPub Med ID
A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface
Sandhya Bangaru 1 , Shanshan Lang 2 , Michael Schotsaert 3 , Hillary A Vanderven 4 , Xueyong Zhu 2 , Nurgun Kose 5 , Robin Bombardi 5 , Jessica A Finn 1 , Stephen J Kent 4 , Pavlo Gilchuk 5 , Iuliia Gilchuk 5 , Hannah L Turner 2 , Adolfo García-Sastre 6 , Sheng Li 7 , Andrew B Ward 2 , Ian A Wilson 8 , James E Crowe Jr
Cell  177(5)  1136-1152  2019

Show Abstract
31100268 31100268